Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age

Addiction

Volumn 108, Issue 10, 2013, Pages 1700-1703

  Griffiths, Paul ^a   Evans Brown, Michael ^a   Sedefov, Roumen ^a  

^a EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; DESIGNER DRUG; PSYCHOTROPIC AGENT; STREET DRUG;

DRUG LEGISLATION; EDITORIAL; HUMAN; SYNTHESIS; SUPPLY AND DISTRIBUTION;

CANNABINOIDS; DESIGNER DRUGS; HUMANS; LEGISLATION, DRUG; PSYCHOTROPIC DRUGS; STREET DRUGS;

EID: 84884204459     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12287     Document Type: Editorial

References (39)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. EU Drug Markets Report: A Strategic Analysis. Publications Office of the European Union; 2013. Available at: http://www.emcdda.europa.eu/publications/joint-publications/drug-markets (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28KKwHy).
2. Commission on Narcotic Drugs. Resolution 55/1. Promoting International Cooperation in Responding to the Challenges Posed by New Psychoactive Substances. Commission on Narcotic Drugs; 2012. Available at: http://www.unodc.org/documents/commissions/CND-Res-2011to2019/CND-Res-2012/Resolution_55_1.pdf (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28cfwlv).
3. Mexican Seafood. "Spice". Bluelight forum. [Online forum comment]. 2006. Available at: http://www.bluelight.ru/vb/printthread.php?t=270616&pp=40 (accessed 5 June 2013).
4. Griffiths P., Sedefov R., Gallegos A., Lopez D. How globalization and market innovation challenge how we think about and respond to drug use: 'Spice', a case study. Addiction 2010; 105: 951-953.
5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. EMCDDA-Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. Publications Office of the European Union; 2013.
6. United Nations Office on Drugs and Crime. The Challenge of New Psychoactive Substances. United Nations Office on Drugs and Crime; 2013. Available at: http://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28gWW13).
7. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010; 105: 1859-1860.
8. Hermanns-Clausen M., Kneisel S., Szabo B., Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108: 534-544.
9. Winstock A. R., Mitcheson L. R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106: 154-161.
10. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011; 106: 1991-1996.
11. Freeman T. P., Morgan C. J. A., Vaughn-Jones J., Hussain N., Karimi K., Curran H. V. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 2012; 107: 792-800.
12. Home Office. Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales. London: Home Office; 2012. Available at: https://www.gov.uk/government/publications/drug-misuse-declared-findings-from-the-2011-to-2012-crime-survey-for-england-and-wales-csew-second-edition (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28orCCS).
13. Hammersley R. Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 2010; 105: 373.
14. Winstock A. R., Ramsey J. D. Legal highs and the challenges for policy makers. Addiction 2010; 105: 1685-1687.
15. Coulson C., Caulkins J. P. Scheduling of newly emerging drugs: a critical review of decisions over 40 years. Addiction 2012; 107: 766-773.
16. Kleiman M. A. R. Commentary on Coulson & Caulkins (2012): optimizing drug scheduling. Addiction 2012; 107: 774-775.
17. Hughes B., Winstock A. R. Controlling new drugs under marketing regulations. Addiction 2012; 107: 1894-1899.
18. Krajewski K. Against excess. Addiction 2012; 107: 1900-1901.
19. Sheridan J., Atmore B., Russell B. New Zealand to establish fit for purpose regulation for new psychoactive substances. Addiction 2012; 107: 1901-1902.
20. Reuter P. The dangerous charms of the unknown. Addiction 2012; 107: 1902-1903.
21. Freeman T. P., Curran H. V. Supply always comes on the heels of demand: what effects do control strategies have on drug users themselves? Addiction 2012; 107: 1903-1905.
22. Parsons J. No quick fix for legal highs. Addiction 2012; 107: 2053-2054.
23. Rasmussen N. On Speed: The Many Lives of Amphetamine. New York: University Press; 2009.
24. Carroll M., Gallo G. Quaaludes: the Quest for Oblivion. New York: Chelsea House Publications; 1991.
25. Baum R. M. New variety of street drugs poses growing problem. Chem Eng News 1985; 63: 7-16.
26. Benzenhöfer U., Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 2010; 105: 1355-1361.
27. Opaleye E. S., Sanchez Z. M., Moura Y. G., Locatelli D. P., Noto A. R. An anti-inflammatory as a recreational drug in Brazil. Addiction 2011; 106: 225.
28. Henderson G. L. Designer drugs: past history and future prospects. J Forensic Sci 1988; 33: 569-575.
29. Measham F., Wood D. M., Dargan P. I. & Moore K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation 'legal highs' in South London gay dance clubs. J Subst Use 2011; 16: 263-272.
30. Rácz J., Csák R., Faragó R., Vadász V. [The phenomenon of drug change in the interviews with injecting drug users]. Psychiatr Hung 2012; 27: 29-47.
31. van Hout M. C., Bingham T. 'A costly turn on': patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy 2012; 23: 188-197.
32. Medicines and Healthcare Products Regulatory Agency. MHRA to remove popular sports supplement used by international athletes from the market. Medicines and Healthcare Products Regulatory Agency; 2012. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON180711 (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28yMkz7).
33. Venhuis B. J., de Kaste D. Scientific opinion on the regulatory status of 1, 3-dimethylamylamine (DMAA). Eur J Food Res Rev 2012; 2: 93-100.
34. Amazon.co.uk. Phenibut. Available at: http://www.amazon.co.uk/s/ref=nb_sb_noss_1?url=search-alias%3Daps&field-keywords=phenibut (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I28teQ9o).
35. Assael S. Steroid Nation. New York: ESPN; 2007.
36. Dyer J. E. γ-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9: 321-324.
37. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Risk assessment report on a new psychoactive substance: 5-(2-aminopropyl)indole. European Monitoring Centre for Drugs and Drug Addiction; 2013. Available at: http://register.consilium.europa.eu/pdf/en/13/st08/st08693.en13.pdf (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I2Cq5UW9)
38. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Office for Official Publications of the European Communities; 2002.
39. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Action on New Drugs. 2013. Available at: http://www.emcdda.europa.eu/activities/action-on-new-drugs (accessed 5 June 2013) (Archived by WebCite® at http://www.webcitation.org/6I290qBPy)